Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118061 | 0.77 | KMT2A (0.63) | CYP2C19GRM5KDM4EMEN1KMT2A | |
| SCHEMBL5123094 | 0.75 | VHL (0.43) | GRM5CYP3A4 | |
| SCHEMBL5121798 | 0.75 | MEN1 (0.47) | GRM5KDM4EMEN1KMT2ALMNA | |
| SCHEMBL5129768 | 0.74 | GRM5 (0.54) | GRM5 | |
| SCHEMBL5119623 | 0.74 | TP53 (0.51) | GRM5KDM4EMEN1KMT2ALMNA | |
| SCHEMBL5124552 | 0.74 | KMT2A (0.49) | GRM5MEN1KMT2ALMNAHTT | |
| SCHEMBL5129058 | 0.73 | MEN1 (0.50) | GRM5POLBMEN1KMT2ALMNA | |
| SCHEMBL5118736 | 0.72 | PTPN11 (0.46) | GRM5MEN1KMT2ALMNAHTT | |
| SCHEMBL5130079 | 0.72 | ALDH1A1 (0.59) | CYP1A2CYP2C9CYP2C19GRM5POLB | |
| SCHEMBL5125577 | 0.72 | PKM (0.47) | CYP1A2CYP2C9CYP2C19GRM5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | CYP1A2 1711/4885CYP2C9 2368/4885CYP2C19 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.